Rare Diseases Treatment Market : By Industry Trends, Leading Players, Size, Share, Growth, Opportunity And Forecast 2024-2033


Posted May 6, 2024 by amrutaptbrc

Rare Diseases Treatment Market : By Industry Trends, Leading Players, Size, Share, Growth, Opportunity And Forecast 2024-2033
 
Overview and Scope
Rare diseases are diseases that impact only a small portion of the population. These diseases have a high death rate since there is little research being done on how to treat them. Rare disease treatment treats rare diseases such as genetic and metabolic diseases.

Sizing and Forecast
The rare diseases treatment market size has grown rapidly in recent years. It will grow from $169.56 billion in 2023 to $192.22 billion in 2024 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to orphan drug legislation, increased disease awareness, biotechnological innovations, global health initiatives, rise in personalized medicine..

The rare diseases treatment market size is expected to see rapid growth in the next few years. It will grow to $312.46 billion in 2028 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to emergence of innovative therapeutic modalities, evolving healthcare reimbursement policies, artificial intelligence and data analytics, expansion of patient registries, regulatory support for expedited approvals.. Major trends in the forecast period include gene therapy breakthroughs, cross-sector collaboration, telemedicine and remote care, emerging therapeutic modalities, patient advocacy and empowerment..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

Segmentation & Regional Insights
The rare diseases treatment market covered in this report is segmented –

1) By Drug Type: Originator Drugs (Patented Molecules), Generic Drugs
2) By Drug Class: Biologics, Organic Compounds
3) By Mode Of Administration: Injectable, Oral, Other Modes Of Administration
4) By Therapeutic Area: Cancer, Neurological Conditions, Cardiovascular Conditions, Musculoskeletal Conditions, Hematologic Disorders, Infectious Diseases, Metabolic Disorders, Endocrine Disorders, Other Therapeutic Areas
5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies

North America was the largest region in the rare disease treatment market in 2023. The regions covered in the rare diseases treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8248&type=smp

Major Driver Impacting Market Growth
The increasing burden of rare diseases is driving the rare disease treatment market. Rare diseases are diseases that affect a very small population as compared to general diseases. The increasing incidences and fatalities due to rare diseases are creating a demand for effective rare diseases treatment. For instance, according to a report published in Orphanet Journal of Rare Diseases, a UK-based open access medical journal on rare diseases, there were about 15.5 million U.S children with at least one rare. As a result, the increasing prevalence of rare diseases propels the rare disease treatment market forward.

Key Industry Players
Major companies operating in the rare diseases treatment market report are AbbVie Inc., Actelion Pharmaceuticals Ltd, Alexion Pharmaceuticals Inc., Celgene Corporation, Bayer AG, Johnson & Johnson, Novartis AG, Pfizer Inc, Sanofi S.A., Eisai Co. Ltd., Merck & Co. Inc., Vertex Pharmaceuticals, Takeda Pharmaceutical Company, Eli Lilly and Company, AstraZeneca plc, Abeona Therapeutics Inc., Akcea Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amicus Therapeutics Inc., BioMarin Pharmaceutical Inc., bluebird bio Inc., Catalyst Pharmaceuticals Inc., Cerecor Inc., Chiesi Farmaceutici S.p.A., CSL Behring Ltd., Dicerna Pharmaceuticals Inc., Diplomat Pharmacy Inc., Esperion Therapeutics Inc., Genzyme Corporation, Horizon Therapeutics plc., Intercept Pharmaceuticals Inc., Ionis Pharmaceuticals Inc.

The rare diseases treatment market report table of contents includes:


1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis


Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By amrutaptbrc
Country United Kingdom
Categories Business
Last Updated May 6, 2024